Turning Point Therapeutics, Inc. Common Stock
TPTX
TPTX was delisted on the 16th of August, 2022.
155 hedge funds and large institutions have $1.24B invested in Turning Point Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 66 increasing their positions, 53 reducing their positions, and 40 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 53
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less funds holding
Funds holding: 172 → 155 (-17)
38% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 40
42% less capital invested
Capital invested by funds: $2.15B → $1.24B (-$905M)
98% less call options, than puts
Call options by funds: $5K | Put options by funds: $236K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$22.7M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$13.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.5M |
| 5 |
Morgan Stanley
New York
|
+$7.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$26.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.6M |
| 3 |
AG
Artal Group
Luxembourg
|
-$11.9M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$11.5M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$8M |
TPTX Hedge Fund Activity: Q1 2022 in Review
155 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q1 2022, worth a combined $1.24B — down 42% from $2.15B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of TPTX and 25 opened new positions — a net loss of 15 holders — while 53 trimmed existing stakes and 66 added.
The largest buyer was State Street, adding an estimated $28.4M. The largest seller was American Century Companies, exiting entirely with an estimated $26.1M sold.
- 155 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q1 2022, down from 172 in Q4 2021.
- Funds reported $1.24B of Turning Point Therapeutics, Inc. Common Stock stock for Q1 2022, down 42% quarter-over-quarter.
- 25 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q1 2022 and 40 closed out, a net change of -15 holders.
- The largest Turning Point Therapeutics, Inc. Common Stock buyer in Q1 2022 was State Street, an estimated $28.4M added.
- The largest Turning Point Therapeutics, Inc. Common Stock seller in Q1 2022 was American Century Companies, an estimated $26.1M sold.
Based on aggregated 13F filings for Q1 2022.